| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c930c1a3fcc9a93dc304ab4a77bd0ea3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca21c29aaa0f8648acd7434e56b839c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_222fdb3e2668d1c9e2b5838193d9d861 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate |
2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7198f8bec959b22b84fd01ed5649ca0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_054885cec775b8bc36f4f01eb14ded81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f430b3e901fe7042fb22061a50ce610b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f922a3f97608bbf91020e83066c093c |
| publicationDate |
2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019151304-A1 |
| titleOfInvention |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory |
| abstract |
The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases. The inventors showed that orexin receptor antagonists have anti-inflammatory properties. Indeed, these compounds are antagonist for OX1R-mediated calcium mobilization but a full agonist for OX1R-mediated mitochondrial apoptosis, which is the mechanism involved in the improvement of resolution of inflammation observed in the models of colitis, multiple sclerosis and pancreatitis. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R antagonist. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023097111-A3 |
| priorityDate |
2016-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |